Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;29(4):2400033.
doi: 10.2807/1560-7917.ES.2024.29.4.2400033.

Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg

Corinna Ernst  1   2 , Dritan Bejko  1 , Leo Gaasch  3 , Emilie Hannelas  3 , Isaline Kahn  3 , Charlotte Pierron  3 , Nesrine Del Lero  3 , Claude Schalbar  3 , Elsa Do Carmo  3 , Michel Kohnen  4 , Emmanuelle Andlauer  5 , Pauline Hublart  1 , Silvana Masi  1 , Isabel de la Fuente Garcia  3 , Anne Vergison  1 , Joël Mossong  1
Affiliations

Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg

Corinna Ernst et al. Euro Surveill. 2024 Jan.

Abstract

After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants < 6 months old (n = 72) seemed to decrease compared to the same period in 2022 (n = 232). In 2023, hospitalised children's mean age increased (14.4 months vs 7.8 months in 2022; p < 0.001) and hospital-stay length decreased (3.2 days vs 5.1 days; p < 0.001). In infants < 6 months old, intensive-care unit admissions appeared to drop (n = 28 vs 9). This suggests that nirsevimab prophylaxis reduced severe RSV infections, particularly in infants < 6 months old, thereby alleviating healthcare strain.

Keywords: Immunisation; Luxembourg; Nirsevimab; Paediatric hospitalization; Real-world evidence; Respiratory Syncytial Virus.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Respiratory syncytial virus (RSV) hospital admission of children under 5 years of age by week in Luxembourg’s national paediatric hospital, Luxembourg, 2022–2023 (n = 668)
Figure 2
Figure 2
Age distribution of children hospitalised with respiratory syncytial virus (RSV) infection in Luxembourg’s national paediatric hospital in weeks 39–52, Luxembourg, 2022–2023 (n = 630)
See this image and copyright information in PMC

References

    1. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Respiratory Virus Global Epidemiology Network. RESCEU investigators . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-64. 10.1016/S0140-6736(22)00478-0 - DOI - PMC - PubMed
    1. Munkstrup C, Lomholt FK, Emborg HD, Møller KL, Krog JS, Trebbien R, et al. Early and intense epidemic of respiratory syncytial virus (RSV) in Denmark, August to December 2022. Euro Surveill. 2023;28(1):2200937. 10.2807/1560-7917.ES.2023.28.1.2200937 - DOI - PMC - PubMed
    1. Broberg EK, Nohynek H. Respiratory syncytial virus infections - recent developments providing promising new tools for disease prevention. Euro Surveill. 2023;28(49):2300686. 10.2807/1560-7917.ES.2023.28.49.2300686 - DOI - PMC - PubMed
    1. Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. HARMONIE Study Group . Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023;389(26):2425-35. 10.1056/NEJMoa2309189 - DOI - PubMed
    1. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. MELODY Study Group . Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-46. 10.1056/NEJMoa2110275 - DOI - PubMed

Substances

LinkOut - more resources